A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors

Conclusions The 20 gene model described in this summary is the first published model for predicting nodal involvement in bladder cancer patients and by providing this molecular intelligence, has the potential to strategically increase the use of neoadjuvant therapy and increase bladder cancer survival rates while limiting unnecessary aggressive treatment. Importantly, the model was developed with clinical applicability in mind. Specifically, the 20 genes (21 probes) used in the model are reliably expressed in TUR specimens and can be reliably detected with both FF and FFPE preservation methods, the clinical conditions under which the model will be employed and allowing for retrospective analysis of archival tissue after the patients has undergone TUR in the course of routine clinical care and muscle invasive disease discovered. Although the model has been validated in prospectively collected samples from an independent clinical trial, further refinement is needed in the clinical laboratory setting to bring this test to routine clinical use. Nevertheless, the development of the model is an important milestone on the path to the personalized treatment of bladder cancer. Links None identified Last updated: August 4, 2011 Competing interests GD and DT participated in the development and validation of the gene model and are coauthors on the publication describing its development and validation [17]. IP rights on this test have been filed at the University of Colorado.
Source: PLOS Currents Evidence on Genomic Tests - Category: Genetics & Stem Cells Authors: Source Type: research